Should we be using kidneys from hepatitis C virus-infected donors?
Beatriz Domínguez‐Gil(Universidad de Zaragoza), José Morales, Josep M. Campistol(Universitat de Barcelona), Amado Andrés(Hospital Universitario 12 De Octubre)
Cited by 6
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566
Donation after circulatory death today: an updated overview of the European landscape
|Transplant International|2019|317
COVID-19 pandemic and worldwide organ transplantation: a population-based study
|The Lancet Public Health|2021|312